New antibody for dermatitis set to move into late-stage trials

7 July 2023
aslanbig

Shares in Singapore and California, USA-based biotech ASLAN Pharmaceuticals (Nasdaq: ASLN) have fallen by a quarter as traders pore over mid-stage data for lead candidate eblasakimab.

The top-line results show the Phase IIb dose-ranging study met its primary endpoint, a measure of efficacy in treating adults with moderate-to-severe atopic dermatitis (AD).

However, the data also show a high response from the placebo arm, a factor which appears to have confused the picture somewhat.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology